Rinsky Batya, Hagbi-Levi Shira, Elbaz-Hayoun Sarah, Grunin Michelle, Chowers Itay
Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Mol Vis. 2017 Dec 6;23:889-899. eCollection 2017.
Oral vitamin and mineral supplements reduce the risk of visual loss in age-related macular degeneration (AMD). However, the pathways that mediate this beneficial effect are poorly understood. Macrophages may exert oxidative, inflammatory, and angiogenic effects in the context of AMD. We aim to assess if oral supplements can modulate the macrophage phenotype in this disease.
Monocytes were isolated from patients with neovascular AMD (nvAMD), cultured, matured to macrophages, and polarized to classical [M1 (stimulated by IFNγ and lipopolysaccharide (LPS))] and alternative [M2 (stimulated with IL-4 and IL-13)] phenotypes. Combinations of antioxidants including lutein+zeaxanthin (1 μM; 0.2 μM), zinc (10 µM), carnosic acid (2 µM), beta-carotene (2 µM), and standardized tomato extract containing lycopene and other tomato phytonutrients were added to the culture media. Levels of anti-inflammatory, antioxidant, and pro-angiogenic gene and protein expression were then evaluated.
Combinations of lutein and carnosic acid with zinc and standardized tomato extract or with beta-carotene yielded an antioxidative, anti-inflammatory, and antiangiogenic effect in M1 and M2 macrophages. These effects manifested in the upregulation of antioxidative genes (HMOX1, SOD1) and the downregulation of pro-angiogenic genes and pro-inflammatory genes (SDF-1, TNF-alpha, IL-6, MCP-1). Lutein monotherapy or a combination of lutein and zinc had less effect on the expression of these genes.
Combinations of supplements can modify the expression of genes and proteins that may be relevant for the involvement of macrophages in the pathogenesis of AMD. Further studies are required to evaluate if the modulation of the macrophage phenotype partially accounts for the beneficial effect of oral supplements in AMD and if modification of the AREDS formula can improve its effect on macrophages.
口服维生素和矿物质补充剂可降低年龄相关性黄斑变性(AMD)患者视力丧失的风险。然而,介导这种有益作用的途径尚不清楚。巨噬细胞可能在AMD的背景下发挥氧化、炎症和血管生成作用。我们旨在评估口服补充剂是否能调节该疾病中的巨噬细胞表型。
从新生血管性AMD(nvAMD)患者中分离单核细胞,进行培养,使其成熟为巨噬细胞,并极化至经典型[M1(由IFNγ和脂多糖(LPS)刺激)]和替代型[M2(由IL-4和IL-13刺激)]表型。将包括叶黄素+玉米黄质(1μM;0.2μM)、锌(10μM)、肌醇六磷酸(2μM)、β-胡萝卜素(2μM)以及含有番茄红素和其他番茄植物营养素的标准化番茄提取物的抗氧化剂组合添加到培养基中。然后评估抗炎、抗氧化和促血管生成基因及蛋白表达水平。
叶黄素与肌醇六磷酸联合锌和标准化番茄提取物或与β-胡萝卜素在M1和M2巨噬细胞中产生抗氧化、抗炎和抗血管生成作用。这些作用表现为抗氧化基因(HMOX1、SOD1)上调,促血管生成基因和促炎基因(SDF-1、TNF-α、IL-6、MCP-1)下调。叶黄素单一疗法或叶黄素与锌的组合对这些基因的表达影响较小。
补充剂组合可改变可能与巨噬细胞参与AMD发病机制相关的基因和蛋白表达。需要进一步研究来评估巨噬细胞表型的调节是否部分解释了口服补充剂对AMD的有益作用,以及修改年龄相关性眼病研究组(AREDS)配方是否能改善其对巨噬细胞的作用。